Oliver Wyman May 12, 2022
Tobias Handschuh


Global #pharmceutical sales took a hit during #COVIDlockdowns, some dropping 10% or more. Some are rebounding. Our analysis looks at 4 areas & their projected return to normal. #OWHealth

During the height of the COVID-19 pandemic, health systems and other providers across the globe were forced to take drastic actions as utilization reached capacity. Hospitals and governments halted elective procedures. Imaging services were prioritized for the most critical patients. Staffing resources were redirected to COVID-stricken patients.

The impact of these actions rippled across the industry. In England and Wales, roughly 2.4 million operations were estimated to have been cancelled in 2021. During three-month period in 2020, US hospitals were projected to have lost $22.3 billion from the cancelation of elective...

Today's Sponsors

Canton & Company
Curation Health

Today's Sponsors

Oliver Wyman

Today's Sponsor

Canton & Company

Topics: Healthcare System, Pharma, Pharma / Biotech, Public Health / COVID
The post-Covid New Normal: a golden opportunity for the NHS?
BA.5's fast rise to dominance: 5 things to know about the omicron subvariant
‘All-In-One’ Vaccine Could Protect Against Future Covid-19 Variants, Researchers Say
Provider Compensation, Productivity Increased to Pre-Pandemic Levels
Highly transmissible Omicron subvariant BA.5 has taken over the US: It takes immune escape ‘to the next level’